<DOC>
	<DOCNO>NCT01780246</DOCNO>
	<brief_summary>The primary objective study examine safety tolerability nusinersen ( ISIS 396443 ) administer intrathecally participant Spinal Muscular Atrophy ( SMA ) previously participate ISIS 396443-CS1 ( NCT02865109 ) . The secondary objective examine plasma pharmacokinetics single dose ISIS 396443 administer intrathecally participant SMA previously participate ISIS 396443-CS1 .</brief_summary>
	<brief_title>An Open-label Safety Tolerability Study Nusinersen ( ISIS 396443 ) Participants With Spinal Muscular Atrophy Who Previously Participated ISIS 396443-CS1 ( NCT01494701 )</brief_title>
	<detailed_description>This study conduct protocol register Ionis Pharmaceuticals , Inc . In August 2016 , sponsorship trial transfer Biogen .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Key Clinical sign attributable Spinal Muscular Atrophy Satisfactory completion dose study visit ISIS 396443CS1 ( NCT01494701 ) acceptable safety profile , per Investigator judgement . Able complete study procedure , measurement visit parent/participant adequately supportive psychosocial circumstance , opinion investigator Estimated life expectancy &gt; 2 year Screening Meets ageappropriate institutional criterion use anesthesia/sedation , use plan study procedure Key Have new worsen exist condition opinion Investigator would make participant unsuitable enrollment , could interfere participant participate complete study . Dosing ISIS 396443CS1 ( NCT01494701 ) within 270 day ( 9 month ) screening , long ago 450 day ( 15 month ) Dosing ISIS 396443CS2 ( NCT01703988 ) Hospitalization surgery ( i.e . scoliosis surgery ) pulmonary event within 2 month screen plan duration study Presence untreated inadequately treat active infection require systemic antiviral antimicrobial therapy time screen period Clinically significant abnormality hematology clinical chemistry parameter Treatment investigational drug , biological agent , device within 1month Screening 5 halflives study agent , whichever longer . Treatment valproate hydroxyurea within 1 month screen . Any history gene therapy cell transplantation NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Spinal Muscular Atrophy</keyword>
	<keyword>SMA</keyword>
	<keyword>SMN</keyword>
	<keyword>SMNRx</keyword>
	<keyword>ISIS-SMNRx</keyword>
	<keyword>ISIS 396443</keyword>
</DOC>